Bio-Rad Laboratories, Inc. (BIO)
Stock Price Chart
Key Info
| Market Cap | 16.43B |
| Revenue (ttm) | 2.38B |
| Net Income (ttm) | 3.52B |
| Shares Out | 29.72M |
| EPS (ttm) | 116.69 |
| PE Ratio | 4.71 |
| Forward PE | 45.25 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 2 |
| Last Price | $549.60 |
| Previous Close | $557.28 |
| Change ($) | -7.68 |
| Change (%) | -1.38% |
| Day's Open | 557.92 |
| Day's Range | 543.16 - 557.92 |
| Day's Volume | 248,473 |
| 52-Week Range | 320.01 - 643.45 |
More Stats
| Market Cap | 16.43B |
| Enterprise Value | 15.91B |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 29.72M |
| Float | n/a |
| EPS (basic) | 118.31 |
| EPS (diluted) | 116.69 |
| FCF / Share | 12.42 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 21.23% |
| FCF Yield | 2.25% |
| Payout Ratio | n/a |
| Shares Short | 387,584 |
| Short Ratio | 2.48 |
| Short % of Float | n/a |
| Beta | 1.00 |
| PE Ratio | 4.71 |
| Forward PE | 45.25 |
| P/FCF Ratio | 44.50 |
| PS Ratio | 6.90 |
| PB Ratio | 1.81 |
| Revenue | 2.38B |
| Operating Income | 294.92M |
| Net Income | 3.52B |
| Free Cash Flow | 369.21M |
| Net Cash | 514.58M |
| Net Cash / Share | 17.21 |
| Gross Margin | 53.00% |
| Operating Margin | 12.39% |
| Profit Margin | 147.90% |
| FCF Margin | 15.51% |
| ROA | 2.11% |
| ROE | 50.45% |
| ROIC | 54.90% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,312 | 2,289 | 2,160 | 2,068 | 2,019 | 2,175 | 2,133 | 2,069 | 2,074 | 1,927 |
| Revenue Growth | 0.97% | 5.98% | 4.45% | 2.41% | -7.15% | 1.99% | 3.07% | -0.21% | 7.6% | - |
| Gross Profit | 1,257 | 1,223 | 1,188 | 1,138 | 1,122 | 1,179 | 1,178 | 1,155 | 1,179 | 1,091 |
| Operating Income | 230 | -103 | 119 | 55.72 | 167 | 150 | 169 | 264 | 305 | 284 |
| Net Income | 1,759 | 366 | 122 | 26.00 | 109 | 88.85 | 77.79 | 165 | 179 | 185 |
| Shares Outstanding | 29.84 | 29.84 | 29.66 | 29.44 | 29.19 | 28.88 | 28.59 | 28.29 | 28.03 | 27.67 |
| Earnings Per Share | 58.27 | 12.10 | 4.07 | 0.88 | 3.71 | 3.05 | 2.69 | 5.78 | 6.29 | 6.59 |
| EPS Growth | 381.57% | 197.3% | 362.5% | -76.28% | 21.64% | 13.38% | -53.46% | -8.11% | -4.55% | - |
| Operating Cash Flow | 458 | 285 | 104 | 216 | 186 | 273 | 169 | 266 | 263 | 226 |
| Capital Expenditures | -98.40 | -126 | -111 | -141 | -112 | -121 | -105 | -137 | -103 | -87.26 |
| Free Cash Flow | 359 | 160 | -7.11 | 75.03 | 74.29 | 153 | 63.69 | 130 | 160 | 139 |
| Cash & Equivalents | 1,120 | 850 | 761 | 844 | 790 | 698 | 609 | 921 | 813 | 1,032 |
| Total Debt | 651 | 439 | 435 | 435 | 434 | 436 | 437 | 734 | 733 | 964 |
| Net Cash / Debt | 469 | 411 | 326 | 409 | 356 | 262 | 172 | 187 | 80.60 | 67.33 |
| Assets | 8,009 | 5,611 | 4,273 | 3,851 | 3,710 | 3,341 | 3,389 | 3,444 | 3,097 | 3,063 |
| Liabilities | 2,254 | 1,591 | 1,343 | 1,271 | 1,219 | 1,156 | 1,202 | 1,428 | 1,352 | 1,522 |
| Book Value | 5,755 | 4,020 | 2,930 | 2,579 | 2,491 | 2,185 | 2,187 | 2,015 | 1,744 | 1,537 |
Company Profile
Company Details
| Full Name | Bio-Rad Laboratories, Inc. |
| Country | United States |
| Employees | 8,000 |
| CEO | Norman Schwartz |
Stock Information
| Ticker Symbol | BIO |
| Stock Exchange | NYSE |
| Share Class | Class A Shares |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NYSE: BIO |
Description
Bio-Rad Laboratories develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.